MTF Biologics

Name

MTF Biologics

Legal name

Musculoskeletal Transplant Foundation

Website

https://mtfbiologics.org

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Allograft Tissue Products

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industries

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair) (HLAHAEAF)

Keywords

• Allograft tissue products
• Human tissue banking
• Orthopedic biologics
• Reconstructive surgery grafts
• Advanced wound care allografts

Headquarters

HQ city

Edison

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Allograft Tissue Distribution: Distribution of processed human allograft tissues to healthcare providers for use in reconstructive surgery, orthopedics, wound care, and aesthetic procedures. Revenue generated from sale of tissue products to hospitals, surgeons, and clinics.
2. Group Purchasing Agreements: Contractual agreements with healthcare group purchasing organizations like Premier, Inc. providing access to MTF Biologics' portfolio of ortho biologics and soft tissue offerings.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

MTF Biologics recovers, aseptically processes, and distributes human allograft tissues to healthcare providers. Its portfolio includes acellular dermal matrices (FlexHD), placental membranes (AmnioBand), demineralized bone matrices (DBX family), viable cartilage allografts (CartiMax), adipose matrices (Renuva, Leneva), dermal wound grafts (AlloPatch, SomaGen), and specialized cartilage/bone products for orthopedic, plastic/reconstructive, and wound care applications. The company also provides Graft Matching services for anatomically-matched osteochondral allografts.

Product overview

MTF Biologics is a nonprofit global organization and the world's largest tissue bank, offering a comprehensive portfolio of allograft tissue products for orthopedic, plastic/reconstructive surgery, and wound care applications. The product portfolio includes acellular dermal matrices (FlexHD® Pliable, FlexHD® Meshed), placental tissues (AmnioBand® Membrane, AmnioBand® Viable), demineralized bone matrix products (DBX® family including DBX® Fiber and Summit Matrix™), cartilage allografts (CartiMax®), adipose tissue products (Renuva®, Leneva®), dermal matrices (AlloPatch® Pliable, AlloPatch® Pliable Meshed, SomaGen® Meshed), and surgical solutions (LipoGrafter®, Profile® Costal Cartilage, Meso BioMatrix®). The company also offers graft matching services and operates with a 100% aseptic processing methodology without terminal radiation, preserving tissue integrity and biological properties.

Differentiator

Problem solved

Functional benefit

Products and services

• FlexHD® Pliable Acellular dermal matrix (ADM) cut from the deeper reticular layer of dermis for improved handling and clinical efficacy in plastic and reconstructive surgery. Used in implant-based breast reconstruction and other procedures, with 100,000+ procedures performed since 2012.
• FlexHD® Meshed Pre-meshed acellular dermal allograft designed for complex soft tissue defects in reconstructive surgery. Eliminates intraoperative preparation and reduces operating room time while providing flexible coverage for irregular wound geometries.
• AmnioBand® Membrane Dehydrated human amnion/chorion allograft (dHACA) for use as acute or chronic wound covering. Retains structural properties of extracellular matrix and inherent growth factors for wound healing. Used in diabetic foot ulcers, venous leg ulcers, and complex wounds (75% wound closure rate in venous leg ulcers at 12 weeks).
• AmnioBand® Viable Membrane Aseptically processed viable human amnion membrane for use as acute or chronic wound covering in wound care applications.
• CartiMax® Viable Cartilage Allograft Ready-to-use, off-the-shelf viable cartilage allograft for knee, foot and ankle. Can fill cartilage defects up to 5cm2 void with shapeable, conformable properties. Stable viability up to one-year post-cryopreservation.
• DBX® Fiber Fiber tissue form in the DBX demineralized bone matrix family designed for complex fusion procedures in orthopedic and spine surgery. Provides improved handling and osteoinductive potential; developed through partnership with Kolosis BIO.
• Summit Matrix™ New biologic solution for orthopedic and spinal surgeries developed through partnership with Kolosis BIO, expanding biologic technologies available for spine and orthopedic procedures.
• DBX® Demineralized Bone Matrix Family Family of demineralized bone matrix products (DBX Mix, DBX Putty, Kore Fiber, and Summit Matrix) for bone void filling and orthopedic procedures. Includes core DBX Mix and DBX Putty plus the 2026-launched DBX Fiber.
• Missouri Osteochondral Preservation System (MOPS℠) Preservation system that doubles storage life of fresh osteochondral allografts, maintaining higher viable chondrocyte density. Used with the Graft Matching service for fresh osteochondral grafts.
• AlloPatch® Pliable Meshed Acellular human reticular dermal allograft with unique meshed design for optimal drainage and incorporation. Designed for diabetic foot ulcers, venous leg ulcers, and other complex chronic wounds.
• SomaGen® Meshed Allograft dermal matrix with meshed design for addressing complex wounds, supporting tissue ingrowth, drainage, and wound closure.
• AlloPatch® Pliable Minimally-processed dermal human allograft derived from deeper reticular layer of dermal tissue for wound care applications.
• Leneva® Allograft Adipose Matrix Allograft adipose matrix for soft tissue defects in face, breast, body, and complex wounds, providing an off-the-shelf alternative to autologous fat grafting.
• Renuva® Allograft Adipose Matrix Allograft adipose matrix made from donated human adipose tissue for soft tissue filling in face, breast and body, providing an alternative to fat grafting without the need for liposuction.
• LipoGrafter® Fat grafting solution for plastic surgeons, providing safe and efficient fat harvesting and delivery technology for better graft survival in aesthetic and reconstructive procedures.
• Profile® Costal Cartilage Pre-cut costal cartilage allograft for rhinoplasty procedures. Allows surgeons to avoid additional surgery to obtain cartilage from the patient's ear or rib.
• Meso BioMatrix® Surgical Mesh Strong, thin xenograft tissue form for cosmetic, plastic and reconstructive surgery requiring soft tissue repair and reinforcement.
• Trinity® Allograft Fresh allograft tissue form for various orthopedic and reconstructive procedures.
• VersaShield® Soft tissue support and reconstruction product in the MTF Biologics portfolio.
• Kore Fiber® Fiber-based tissue form in the Kolosis BIO portfolio for spine and orthopedic procedures, distributed by MTF Biologics.
• QuickGraft® Allograft product in the MTF Biologics portfolio.
• Prime DBM HD™ Bone void filler product for orthopedic reconstruction.
• Conform® Product in the MTF Biologics portfolio.
• Extearna™ Product in the MTF Biologics portfolio.
• Enhance® Product in the MTF Biologics portfolio.
• Graft Matching Service Fully-digital online ordering platform providing anatomically-matched allograft tissue for patients, particularly for large grafts, meniscal, and fresh osteochondral allografts. Surgeons upload films, receive instant confirmation, and connect with the MTF team throughout the process.
• Cardiac Surgery Allografts Two new allograft tissue forms designed to advance cardiac surgery, developed through partnership with Kolosis BIO.

Quantifiable outcome

• 12 million+ grafts distributed with zero viral disease transmission
• +3 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

13 partnerships are on record, tiered core and minor.

• New Horizon Medical SolutionscoreChannel Partner/ Reseller/ Distributor · 21 May 2026Exclusive distributor of AmnioBand Membrane for post-acute and outpatient markets, expanding access to wound care products.
• Kolosis BIOcoreStrategic or Co-development Partner · 31 March 2026Partnership to develop and commercialize the DBX demineralized bone matrix family including DBX Fiber, DBX Mix, DBX Putty, Kore Fiber, and Summit Matrix for spine and orthopedic procedures.
• FDA (U.S. Food and Drug Administration)coreOthers · 2 November 2023Regulatory partnership for FDA IDE approval of FlexHD Pliable for breast reconstruction clinical study.
• Mission PlasticosminorStrategic or Co-development Partner · 30 August 2023Humanitarian partnership providing allograft tissue free of charge to support reconstructive surgery missions for underserved populations.
• Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 27 May 2021Group purchasing agreement providing Premier members access to MTF Biologics' portfolio of ortho biologics and soft tissue offerings including tissue implantable products and bone substitutes.
• BioventuscoreStrategic or Co-development Partner · 6 June 2019Development collaboration to co-develop next generation placental tissue product for treatment of musculoskeletal conditions, with initial focus on knee osteoarthritis.
• ConMedcoreTechnology or Integration · 12 March 2019Partnership for CartiMax Viable Cartilage Allograft - ConMed distributes CartiMax and collaborates on product development for orthopedic applications.
• International Institute for the Advancement of Medicine (IIAM)coreOthers · 12 March 2019Division of MTF Biologics that honors donors of non-transplantable organs by providing gifts to medical research community.
• StatlinecoreOthers · 12 March 2019Division of MTF Biologics providing specialized communications and technology expertise to organ, tissue, and eye procurement organizations.
• Deutsches Institute for Zell-und Gewebeersatz (DIZG)minorOthers · 12 March 2019Sister organization (German Institute for Cell and Tissue Transplantation) expanding reach to patients across the globe.
• Lifeline of OhiocoreOthers · 24 January 2019Tissue recovery agreement - recovers musculoskeletal, dermal and birth tissues on behalf of MTF Biologics.
• Southwest Transplant AlliancecoreOthers · 21 January 2019Tissue recovery partnership - STA recovers musculoskeletal and dermal tissues on behalf of MTF Biologics.
• Academy MedicalminorGTM or Marketing Partner · 1 November 2018Partnership to advance care for veterans through distribution and support of MTF Biologics tissue products.

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• LifeNet Health: Nonprofit tissue bank and the most direct U.S. competitor to MTF Biologics, recovering and distributing allografts (bone, skin, cardiac, vascular, sports medicine) to hospitals and surgeons. Competes head-to-head across orthopedic, spine, and wound-care portfolios, and operates a similarly scaled donor-recovery network.
• AlloSource: Nonprofit tissue bank specializing in allograft bone, skin, and connective tissue for orthopedic, spine, and sports medicine procedures. Closely comparable in business model (501(c)(3) tissue processor with product portfolio spanning DBX-equivalent bone grafts, dermal matrices, and sports medicine allografts).
• Vivex Biologics: For-profit regenerative medicine company distributing allograft products for orthopedic, spine, and wound-care applications. Comparable product portfolio (bone grafts, amniotic membranes, adipose matrices) targeting the same surgeon customers as MTF Biologics.
• Axogen: Specializes in surgical solutions for peripheral nerve repair using allograft and processed nerve tissue, competing with MTF's soft-tissue allograft portfolio in the surgical reconstruction space. While narrower in scope (nerve-focused), it uses a similar allograft-plus-direct-sales GTM.

Emerging players

• MiMedx: Public regenerative medicine company focused on placental tissue allografts (EpiFix, AmnioFix) for wound care and surgical applications. Direct overlap with MTF's AmnioBand and wound-care portfolio, but with a more focused skin/wound-care emphasis and more aggressive commercial expansion.
• Organogenesis: Public regenerative medicine company offering skin and wound-care products (Apligraf, Dermagraft, PuraPly) competing with MTF's AmnioBand and other dermal/wound allografts, particularly in chronic wound and burn applications.

Broad incumbents

• Integra LifeSciences: Large public medical device company with a regenerative tissue technologies portfolio (dermal matrices, dural repair, wound care) that overlaps MTF's reconstructive surgery and wound care segments. Much broader portfolio and global distribution, but not tissue-bank pure-play.
• ConMed (CartiMax distribution partner): Public orthopedic medical-device company that distributes MTF's CartiMax viable cartilage allograft — a commercial partner in sports medicine but also a broader competitor in cartilage repair and orthopedic biologics via its own arthroscopy and sports medicine product lines.
• Stryker: Public orthopedic medical-device giant offering biologics (bone graft substitutes, regenerative products) that compete with MTF's DBX bone matrix portfolio in spine and orthopedic surgery. Not a pure-play tissue bank but a relevant comparand where MTF's orthopedic biologics compete for surgeon share and hospital contracts.

Regional players

• Community Blood Center / Community Tissue Services: Nonprofit tissue bank and blood operator serving similar orthopedic, wound care, and reconstructive surgery customers as MTF, but with a more regional (Midwest) donor/supply footprint. Closest analog to MTF's nonprofit tissue-bank model and donor-recovery operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/MTFBiologics
• Facebookfacebook.com/MTFBiologics
• LinkedInlinkedin.com/company/mtf-biologics
• Instagraminstagram.com/mtfbiologics
• Xx.com/MTFBiologics

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MTF Biologics